Periocular triamcinolone and photodynamic therapy for subfoveal choroidal neovascularization in age-related macular degeneration

Ophthalmology. 2007 Sep;114(9):1713-21. doi: 10.1016/j.ophtha.2007.03.071.

Abstract

Purpose: To evaluate fluorescein angiographic and visual acuity (VA) outcomes from patients enrolled in a trial of a single periocular corticosteroid injection immediately before photodynamic therapy (PDT) versus PDT alone for subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).

Design: Randomized 2-center clinical trial.

Participants: Sixty-seven subjects with AMD, subfoveal choroidal neovascularization, and best-corrected VA of 20/20 to 20/320 in the study eye who had received no more than 1 prior PDT treatment.

Methods: Subjects were randomized to receive PDT alone (no corticosteroid) or a single periocular corticosteroid injection given via the posterior superior sub-Tenon's capsule route before PDT (corticosteroid) and assessed 1, 3, and 6 months after enrollment. Best-corrected VA and intraocular pressure (IOP) measurements were taken during each examination. Color photographs and fluorescein angiograms were taken at baseline and 3 and 6 months.

Main outcome measure: Presence or absence of fluorescein leakage from choroidal neovascularization 3 months after randomization.

Results: Between the 34 participants randomized to periocular corticosteroid and 33 to no corticosteroid, baseline features appeared balanced. Thirty-three corticosteroid participants and 30 no corticosteroid participants returned for the 3-month follow-up, at which time 56 had fluorescein leakage. Proportions of participants with leakage at 3 months for the 2 treatment groups did not statistically significantly differ; 94% of the corticosteroid group and 90% of the no corticosteroid group had fluorescein leakage at 3 months (P = 0.66). Mean VAs at 3 months after enrollment were 20/100 and 20/125 in the corticosteroid and no corticosteroid groups, respectively, decreasing on average 1.5 and 0.9 lines from baseline (P = 0.50). Adverse events included IOP > 21 mmHg in 7 corticosteroid participants (21%) and 1 (3%) no corticosteroid participant (P<0.05) and ptosis of the study eyelid in 1 (3%) corticosteroid participant.

Conclusions: In contrast to previously reported uncontrolled studies and 1 controlled study, this trial did not find a reduction in the amount of fluorescein leakage 3 months after a single periocular injection of corticosteroid and PDT compared with PDT alone.

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Capillary Permeability
  • Choroidal Neovascularization / drug therapy*
  • Choroidal Neovascularization / etiology
  • Choroidal Neovascularization / metabolism
  • Female
  • Fluorescein / metabolism
  • Fluorescein Angiography
  • Fluorescent Dyes / metabolism
  • Fovea Centralis
  • Glucocorticoids / adverse effects
  • Glucocorticoids / therapeutic use*
  • Humans
  • Injections
  • Intraocular Pressure
  • Macular Degeneration / complications
  • Macular Degeneration / drug therapy*
  • Macular Degeneration / metabolism
  • Male
  • Photochemotherapy*
  • Photosensitizing Agents / adverse effects
  • Photosensitizing Agents / therapeutic use
  • Porphyrins / adverse effects
  • Porphyrins / therapeutic use
  • Triamcinolone Acetonide / adverse effects
  • Triamcinolone Acetonide / therapeutic use*
  • Verteporfin
  • Visual Acuity
  • Vitreous Body

Substances

  • Fluorescent Dyes
  • Glucocorticoids
  • Photosensitizing Agents
  • Porphyrins
  • Verteporfin
  • Triamcinolone Acetonide
  • Fluorescein